PMID- 34434611
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20220531
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 10
IP  - 1
DP  - 2021
TI  - PD-1 inhibition in patient derived tissue cultures of human gastric and 
      gastroesophageal adenocarcinoma.
PG  - 1960729
LID - 10.1080/2162402X.2021.1960729 [doi]
LID - 1960729
AB  - Emerging immunotherapies quest for better patient stratification in cancer 
      treatment decisions. Moderate response rates of PD-1 inhibition in gastric and 
      esophagogastric junction cancers urge for meaningful human model systems that 
      allow for investigating immune responses ex vivo. Here, the standardized 
      patient-derived tissue culture (PDTC) model was applied to investigate tumor 
      response to the PD-1 inhibitor Nivolumab and the CD3/CD28 t-lymphocyte activator 
      ImmunoCult(TM). Resident t-lymphocytes, tumor proliferation and apoptosis, as 
      well as bulk gene expression data were analyzed after 72 h of PD-1 inhibition 
      either as monotherapy or combined with Oxaliplatin or ImmunoCult(TM). Individual 
      responses to PD-1 inhibition were found ex vivo and combination with chemotherapy 
      or t-lymphocyte activation led to enhanced antitumoral effects in PDTCs. 
      T-lymphocyte activation as well as the addition of pre-cultured peripheral blood 
      mononuclear cells improved PDTC for studying t-lymphocyte and tumor cell 
      communication. These data support the potential of PDTC to investigate 
      immunotherapy ex vivo in gastric and esophagogastric junction cancer.
CI  - (c) 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Husstegge, Marlon
AU  - Husstegge M
AD  - Institute of Anatomy, University of Leipzig, Leipzig.
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious 
      Diseases, University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, 
      Germany.
FAU - Hoang, Ngoc Anh
AU  - Hoang NA
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious 
      Diseases, University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, 
      Germany.
FAU - Rebstock, Jakob
AU  - Rebstock J
AD  - Institute of Anatomy, University of Leipzig, Leipzig.
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious 
      Diseases, University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, 
      Germany.
FAU - Monecke, Astrid
AU  - Monecke A
AD  - Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.
FAU - Gockel, Ines
AU  - Gockel I
AD  - Department of Visceral, Transplantation, Thoracic and Vascular Surgery, 
      University Hospital Leipzig, Leipzig, Germany.
FAU - Weimann, Arved
AU  - Weimann A
AD  - Department for General and Visceral Surgery, Hospital St. Georg Leipzig, Leipzig, 
      Germany.
FAU - Schumacher, Guido
AU  - Schumacher G
AD  - Department for General and Visceral Surgery, Hospital Braunschweig, Braunschweig, 
      Germany.
FAU - Bechmann, Ingo
AU  - Bechmann I
AD  - Institute of Anatomy, University of Leipzig, Leipzig.
FAU - Lordick, Florian
AU  - Lordick F
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious 
      Diseases, University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, 
      Germany.
FAU - Kallendrusch, Sonja
AU  - Kallendrusch S
AUID- ORCID: 0000-0003-2474-8307
AD  - Institute of Anatomy, University of Leipzig, Leipzig.
FAU - Korfer, Justus
AU  - Korfer J
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious 
      Diseases, University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210818
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Esophageal Neoplasms/*drug therapy
MH  - *Esophagogastric Junction
MH  - Humans
MH  - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use
MH  - Leukocytes, Mononuclear
MH  - Nivolumab/pharmacology/*therapeutic use
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
PMC - PMC8381835
OTO - NOTNLM
OT  - Gastric cancer
OT  - immune response to cancer
OT  - immunology
OT  - immunotherapy
OT  - patient derived tissue culture
COIS- The authors declare no potential conflicts of interest.
EDAT- 2021/08/27 06:00
MHDA- 2021/10/16 06:00
PMCR- 2021/08/18
CRDT- 2021/08/26 06:15
PHST- 2021/08/26 06:15 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/08/18 00:00 [pmc-release]
AID - 1960729 [pii]
AID - 10.1080/2162402X.2021.1960729 [doi]
PST - epublish
SO  - Oncoimmunology. 2021 Aug 18;10(1):1960729. doi: 10.1080/2162402X.2021.1960729. 
      eCollection 2021.